Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2022
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Sundeep Agrawal, Haley Gittleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 21, 2021
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerAnand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast CancerHarpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2021
Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case ExamplesAnup K Amatya, Mallorie H Fiero, Erik W Bloomquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in ReviewShaily Arora, Preeti Narayan, Christy L Osgood, et al.
Pageof 6